ORIGINALLY PUBLISHED
3 September 2025
Written by:
Vice President, Head of Enterprise Data Enablement, Enterprise Data Unit, AstraZeneca
Vice President, External R&D and Strategic Alliances, Oncology R&D, AstraZeneca
Breakthrough discoveries rarely happen in isolation. They emerge when dynamic partnerships bring together bright minds from diverse disciplines, enabling new perspectives and collaborative problem-solving. This has never been more evident in drug discovery than now, as academia and industry work together to reshape the field at the intersection of human expertise and artificial intelligence (AI).
At AstraZeneca, we are harnessing the power of AI by embedding it into every stage of drug development. We're dedicated to building novel AI solutions both in-house and with external partners, forming strategic collaborations that accelerate and enhance our processes. This collaborative approach acknowledges the rapid pace of AI development and the complexity of modern drug discovery, underscoring the need for innovation and deep expertise to deliver next-generation therapeutics.
Because of the sheer scale and millions of variables inherent in drug discovery, AI’s strengths hold tremendous promise in this field. The complexity of analysing extensive datasets and identifying meaningful patterns is precisely where AI excels, enabling us to draw actionable insights that inform our research and make it more efficient and selective.
A strategic alliance driving innovation
Our unique alliance with Stanford Medicine exemplifies how industry and academia can join forces to push the boundaries of pharmaceutical research. This collaboration brings together AstraZeneca's drug development expertise with Stanford University's excellence in computer science, engineering, and biomedical research.
Focused on novel AI-driven approaches for cardiovascular, renal and metabolism, oncology, and rare diseases, our teams work closely together to help advance targeted medicine discovery and improve clinical trial design.
Unlike many collaborations defined by specific projects, this strategic alliance centres on leveraging the strengths of both organisations. By building a long-term, trust-based relationship with a broad scope, both teams can draw upon their unique strengths, identify ambitious research questions, and apply orthogonal thinking for maximum impact.
We are thrilled to collaborate with Stanford Medicine, leveraging our shared vision of harnessing AI to transform drug discovery. It enables us to incorporate diverse expertise from other fields into pharmaceutical research, unlocking innovation and new opportunities to deliver potentially life-changing medicines to patients, faster.
Industry – academia collaborations with complementary strengths create possibilities neither organisation could achieve alone. Solving hard scientific problems requires bringing together experts from multiple disciplines—biologists, data scientists, ethicists— all working towards shared goals.
Strategic academic collaborations are fundamental to advancing AI in drug discovery. By combining our industry expertise with world-class academic research capabilities, we have the potential to accelerate breakthrough science and ultimately help deliver better outcomes for patients.
Through collaboration, we are building an AI innovation ecosystem that could help deliver the next generation of potentially life-changing therapies to patients who need them most.
Want to know more?
Discover how we're advancing AI across our research pipeline, explore our approach to responsible AI innovation, and find out about our strategic partnerships driving the development and delivery of breakthrough medicines worldwide.
